Dual-therapy ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 50 | Dermatomyositis | 1 |
50. Dermatomyositis
Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05375435 (ClinicalTrials.gov) | January 1, 2022 | 11/5/2022 | Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis | Efficacy and Safety of Triple Therapy Based on Prognostic Risk Stratification in Patients With Anti-MDA5 Antibody-positive Dermatomyositis: a Multicenter, Prospective, Randomized Controlled Study | Dermatomyositis, Adult Type;Interstitial Lung Disease | Drug: triple therapy;Drug: dual-therapy | The First Affiliated Hospital with Nanjing Medical University | NULL | Recruiting | 18 Years | N/A | All | 120 | Phase 4 | China |